Display options
Cite
Yokoyama S, Nakagawa C, Hosomi K. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. Support Care Cancer. 2021;30(2):1765-1773doi: 10.1007/s00520-021-06585-z.
Yokoyama, S., Nakagawa, C., & Hosomi, K. (2022). Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30(2), 1765-1773. https://doi.org/10.1007/s00520-021-06585-z
Yokoyama, Satoshi, et al. "Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 30,2 (2022): 1765-1773. doi: https://doi.org/10.1007/s00520-021-06585-z
Yokoyama S, Nakagawa C, Hosomi K. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. Support Care Cancer. 2022 Feb;30(2):1765-1773. doi: 10.1007/s00520-021-06585-z. Epub 2021 Oct 01. PMID: 34595605.
Copy Download .nbib Format: NLM
Share it on

Support Care Cancer. 2022 Feb;30(2):1765-1773. doi: 10.1007/s00520-021-06585-z. Epub 2021 Oct 01.

Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Satoshi Yokoyama, Chihiro Nakagawa, Kouichi Hosomi

Affiliations

  1. Division of Drug Informatics, School of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan. [email protected].
  2. Division of Drug Informatics, School of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan.

PMID: 34595605 DOI: 10.1007/s00520-021-06585-z

Abstract

PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of cancer treatment; however, no drug is recommended for the prevention of CIPN. In Japan, several drugs such as Gosha-Jinki-Gan and duloxetine are frequently administered as a treatment for CIPN. The aim of this study was to elucidate prescription patterns of drugs administered for CIPN caused by oxaliplatin and the association between these drugs and the duration of oxaliplatin treatment.

METHODS: We conducted a retrospective nationwide study using the JMDC administrative claims database (January 2005-June 2020; JMDC Inc., Japan). Patients newly treated with oxaliplatin were identified, and prescription patterns of CIPN medication including Gosha-Jinki-Gan, pregabalin, duloxetine, mecobalamin, and mirogabalin were investigated. The primary outcome was the duration of oxaliplatin treatment. Multivariable logistic regression analysis was performed to examine the association between CIPN medication and duration of oxaliplatin treatment.

RESULTS: A total of 4,739 patients who newly received oxaliplatin were identified. Of these, 759 (16.0%) had received CIPN medication. Duloxetine was administered in 99 (2.1%) patients. Multivariable logistic regression analysis revealed that CIPN medication was significantly associated with the prolonged duration of oxaliplatin treatment (odds ratio: 2.35, [95% confidence interval: 1.99-2.77]).

CONCLUSION: Real-world data demonstrated that the administration rate of CIPN medication was higher in patients who received oxaliplatin treatment for over 6 months.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords: Chemotherapy-induced peripheral neuropathy; Claims database; Duloxetine; Oxaliplatin; Real-world data

References

  1. Argyriou AA, Bruna J, Marmiroli P et al (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77. https://doi.org/10.1016/j.critrevonc.2011.04.012 - PubMed
  2. Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470. https://doi.org/10.1016/j.pain.2014.09.020 - PubMed
  3. Yamamoto S, Egashira N (2020) Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy. Front Pharmacol 11:607780. https://doi.org/10.3389/fphar.2020.607780 - PubMed
  4. Hirayama Y, Yoshida Y, Mori M et al (2020) Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer. Jpn J Clin Oncol 50:897–902. https://doi.org/10.1093/jjco/hyaa056 - PubMed
  5. Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38:3325–3348. https://doi.org/10.1200/jco.20.01399 - PubMed
  6. Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003 - PubMed
  7. Park SB, Lin CSY, Krishnan AV et al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16:708–716. https://doi.org/10.1634/theoncologist.2010-0248 - PubMed
  8. Kawashiri T, Mine K, Kobayashi D et al (2021) Therapeutic agents for oxaliplatin-induced peripheral neuropathy; experimental and clinical evidence. Int J Mol Sci 22. https://doi.org/10.3390/ijms22031393 - PubMed
  9. Kimura S, Sato T, Ikeda S et al (2010) Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 20:413–419. https://doi.org/10.2188/jea.je20090066 - PubMed
  10. Nagai K, Tanaka T, Kodaira N et al (2021) Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med 22:118–127. https://doi.org/10.1002/jgf2.422 - PubMed
  11. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. https://doi.org/10.1200/jco.2008.20.6771 - PubMed
  12. Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471. https://doi.org/10.1200/jco.2010.33.6297 - PubMed
  13. Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321. https://doi.org/10.1016/s0140-6736(11)61873-4 - PubMed
  14. Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367. https://doi.org/10.1001/jama.2013.2813 - PubMed
  15. Argyriou AA, Velasco R, Briani C et al (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23:3116–3122. https://doi.org/10.1093/annonc/mds208 - PubMed
  16. Tanishima H, Tominaga T, Kimura M et al (2017) Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. Support Care Cancer 25:1383–1389. https://doi.org/10.1007/s00520-016-3514-6 - PubMed
  17. Ali NT, Mohamed AA, Yousef BA (2020) The incidence of oxaliplatin-induced peripheral neurotoxicity at Khartoum Oncology Hospital: a cross-sectional survey. Asia Pac J Oncol Nurs 7:266–272. https://doi.org/10.4103/apjon.apjon_12_20 - PubMed
  18. Ibrahim EY, Ehrlich BE (2020) Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol 145:102831. https://doi.org/10.1016/j.critrevonc.2019.102831 - PubMed
  19. Japanese Association of Supportive Care in Cancer (2017). Clinical guide of management for chemotherapy-induced peripheral neuropathy. KANEHARA & Co. Ltd., in Japanese, Tokyo - PubMed
  20. Żok J, Bieńkowski M, Radecka B et al (2021) Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study. BMC Cancer 21:529. https://doi.org/10.1186/s12885-021-08183-y - PubMed
  21. Gu J, Lu H, Chen C et al (2021) Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer. https://doi.org/10.1007/s00520-021-06321-7 - PubMed
  22. Hoshino N, Ganeko R, Hida K et al (2018) Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Int J Clin Oncol 23:434–442. https://doi.org/10.1007/s10147-017-1229-4 - PubMed
  23. Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775. https://doi.org/10.1007/s10147-015-0784-9 - PubMed
  24. Kuriyama A, Endo K (2018) Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer 26:1051–1059. https://doi.org/10.1007/s00520-017-4028-6 - PubMed
  25. de Andrade DC, Jacobsen Teixeira M, Galhardoni R et al (2017) Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial. Oncologist 22:1154-e105. https://doi.org/10.1634/theoncologist.2017-0235 - PubMed
  26. Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866–871. https://doi.org/10.1007/s10147-015-0810-y - PubMed
  27. Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24:394–400. https://doi.org/10.1200/jco.2005.03.0106 - PubMed
  28. Samuels N, Ben-Arye E (2020) Integrative approaches to chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 22:23. https://doi.org/10.1007/s11912-020-0891-2 - PubMed

Publication Types

Grant support